menu search

TNXP / Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) did not significantly reduce fibromyalgia daily pain at Week 14 compared to placebo in the Phase 3 RALLY study.  Tonix reported interim analysis. Read More
Posted: Mar 21 2022, 10:20
Author Name: Benzinga
Views: 103115

TNXP News  

Tonix shares sink 29% on discontinued development on depression treatment

By Market Watch
October 31, 2023

Tonix shares sink 29% on discontinued development on depression treatment

Shares of Tonix Pharmaceuticals TNXP fell Tuesday after the company said it would discontinue development of its treatment for major depressive disord more_horizontal

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?

By InvestorPlace
September 29, 2023

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company priced a share offering. Acc more_horizontal

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

By GlobeNewsWire
August 17, 2023

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed product more_horizontal

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 43% Today?

By InvestorPlace
July 28, 2023

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 43% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is taking a beating on Friday after the company announced a public stock offering. That public stock offe more_horizontal

Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conference

By Proactive Investors
March 23, 2023

Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conference

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp EVP of translation medicine Herbert Harris delivered an oral presentation Thursday at the Rare Diseas more_horizontal

Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodies

By Proactive Investors
February 13, 2023

Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodies

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. said it has exercised an option to obtain an exclusive license from Columbia University for the deve more_horizontal

Using News to Find Penny Stocks to Buy: 3 Tips

By PennyStocks
January 9, 2023

Using News to Find Penny Stocks to Buy: 3 Tips

Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Pic more_horizontal

Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?

By InvestorPlace
December 12, 2022

Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?

Today is a banner day for anyone who happened to hold Tonix Pharmaceuticals (NASDAQ: TNXP ) stock over the weekend. Early this morning, Tonix disclose more_horizontal


Search within

Pages Search Results: